Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima ® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only ...

Hologic’s HOLX Aptima Mycoplasma genitalium assay recently attained significant recognition based on a positive study outcome. A prospective, multi-center Aptima Mycoplasma genitalium Evaluation Study ...

MARLBOROUGH, Mass. - Hologic, Inc. (NASDAQ:HOLX) announced its Aptima HPV Assay has received FDA approval for clinician-collected HPV primary screening, expanding the company’s cervical cancer ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (NASDAQ: HOLX) announces the addition of the Aptima® SARS-CoV-2 assay to its Global Access Initiative (GAI), a program designed to expand access to ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, ...

MARLBOROUGH, Mass., February 04, 2026--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima ® HPV Assay received FDA approval for clinician-collected HPV primary screening.

Screening for cervical cancer is critically important to women’s health. In the United States, it is estimated that in 2026, approximately 13,490 new cases of invasive cervical cancer will be ...

“Hologic has been at the forefront of cervical cancer screening for decades, and the additional indication of the Aptima HPV Assay reflects our ongoing commitment to advancing women’s health through ...

Hologic Inc, a global company offering a broad portfolio for cervical cancer screening, announced that its Aptima HPV assay received US Food and Drug Administration approval for clinician-collected ...